Resonetics Strengthens Bioelectronics Offerings Through Acquisition of Med-Ally's Manufacturing and IP Assets

Resonetics Enhances Bioelectronics Portfolio

In a significant move, Resonetics announced its acquisition of manufacturing assets and intellectual property from Med-Ally, a medical technology company based in Charleston, South Carolina. This strategic acquisition aims to bolster Resonetics’ capabilities in the bioelectronics sector, specifically in the manufacturing of implantable and external pulse generators (IPG/EPG) and their leads.

Strengthening the Medical Power Business

Resonetics is known for its expertise in implantable battery technologies, and this new integration allows the company to offer customers a complete solution that includes both the energy source and the active implantable device. With the potential for growth within neuromodulation, brain-computer interfaces (BCI), and cardiac rhythm management (CRM) markets, this acquisition significantly enhances Resonetics’ medical power business.

Kevin Kelly, the CEO of Resonetics, emphasized the importance of this acquisition, stating, "This acquisition represents an important step forward for our Bioelectronic market segment." Previously, Resonetics was already providing implantable batteries for neurostimulation and cardiac devices. Now, with the capability to manufacture the pulse generators themselves, they can provide an even more integrated and efficient solution to their customers.

A Differentiated Capability in the Industry

Fred Borne, VP of Fiber Optic Sensors and Medical Power at Resonetics, pointed out the competitive advantage created by this acquisition. By combining the expertise of IPG manufacturing and assembly with Resonetics’ implantable battery technology, they now possess a unique capability that sets them apart in the market. This positions them as a comprehensive partner for next-generation neuromodulation devices, a need that has been growing among their customers.

Recent Acquisitions and Future Focus

This acquisition marks the third noteworthy transaction for Resonetics in just twelve months. The company previously expanded its capabilities through other acquisitions, such as nitinol gun-drilling and micro-molding technologies from Medical Component Specialists and Eden Holdings. Resonetics plans to continue targeting niche manufacturing technologies that support the most innovative segments of the medical device industry.

About Resonetics

Founded in 1987, Resonetics has established itself as a leader in advanced engineering and manufacturing solutions designed for the medical device industry. The company excels in laser processing, nitinol manufacturing, and thin-wall stainless steel applications. With over 3,000 employees across multiple locations, including the United States, Canada, and Israel, Resonetics is committed to quality, innovation, and an excellent customer experience. The company maintains ISO 13485:2016 certification and operates several specialized development centers to promote rapid production and prototype options.

For more information about Resonetics and their latest offerings, please visit their official website: www.resonetics.com.

Conclusion

This strategic acquisition not only enhances Resonetics’ overall manufacturing capabilities in the bioelectronics market but also solidifies its position as a key player in delivering top-notch neuromodulation solutions. As the demand for advanced medical devices continues to rise, Resonetics stands ready to meet the challenges of this dynamic industry, ensuring that they remain at the forefront of medical technology innovation.